Dr. Ramprasad C. Dandillaya, MD

Dr. Dandillaya practices at Beverly Hills Endosurgical Center in Beverly Hills, California.

Dr. Dandillaya's NPI, 1316900236, was assigned on April 11, 2006. Dr. Dandillaya graduated from George Washington University School of Medicine and Health Sciences in 2000. Dr. Dandillaya's California license number on file is A77410.

Dr. Dandillaya's primary practice is Beverly Hills Endosurgical Center, at 150 North Robertson Blvd, Suite 110, Beverly Hills, CA 90211. The practice phone is (323) 202-2023.

Dr. Dandillaya's primary practice is Beverly Hills Endosurgical Center in Beverly Hills, California. Dr. Dandillaya is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Dandillaya to 1 more hospital, 4 medical groups, 3 group practices and clinics, 3 home health agencies and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dandillaya practices, 10 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Dandillaya's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Dandillaya is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Dandillaya's licenses on file in 6 states: California, Florida, Arizona, Colorado, Washington and Nevada.

Dmand AI lists acid reflux, acne, acute mini-stroke (TIA), acute sinusitis, acute skin infection, aneurysm, ankle or foot injury and anxiety among the conditions Dr. Dandillaya treats.

CMS data shows 25,363 Medicare services from Dr. Dandillaya across 41 procedure codes in 2024, for 954 Medicare patients. Medicare paid $752,851 for them.

CMS counts 954 Medicare patients who saw Dr. Dandillaya in 2024. The largest group is 65 to 74, with 440 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.08, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Dandillaya's median patient age at 73, with 41% women.

In 2024, Dr. Dandillaya wrote 5,946 Medicare Part D claims for 547 patients. 80% of them were for generic drugs. CMS names the drug for 5,266 of them, across 101 drugs with 11 or more claims each, at $814,553 in total drug cost. In 2023, CMS named 4,368 claims across 91 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Dandillaya for performance year 2024, reported as part of a group. Dr. Dandillaya accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dandillaya as offering telehealth.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links Dr. Dandillaya to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Asthma and Respiratory Hypersensitivity. Open Payments lists research payments to Dr. Dandillaya that name 1 trial.

CMS Open Payments shows 697 general payments to Dr. Dandillaya from 73 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 58% of the total. Vitaphone_USA_Corporation paid the most, $6,795. It also lists 12 research payments totaling $2,210 from 2016 to 2023, naming 1 clinical trial.

Dmand AI lists 2 awards for Dr. Dandillaya, most recently CMS Stage 1 EHR in 2013. Dr. Dandillaya serves on Medical Executive Committee Cedars-Sinai Medical Center.

Dr. Dandillaya graduated from George Washington University School of Medicine and Health Sciences in 2000. Dr. Dandillaya is a member of ACC.

Dr. Dandillaya is in network with 18 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.